# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Ex...
BMO Capital analyst Etzer Darout reiterates C4 Therapeutics (NASDAQ:CCCC) with a Outperform and maintains $20 price target.